TGIA
VRTX icon

Torrey Growth & Income Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Torrey Growth & Income Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Hold
4,710
– – 0.79% 25
2026
Q1 		$2.09M Sell
4,710
-9
-0.2% -$4.2K 0.88% 23
2025
Q4 		$2.14M Sell
4,719
-681
-13% -$294K 0.74% 27
2025
Q3 		$2.11M Buy
+5,400
New +$2.26M 0.62% 32

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Torrey Growth & Income Advisors's VRTX Position: Q2 2026 in Review

Torrey Growth & Income Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 4,710 shares worth $2.34M. The position accounts for 0.79% of the portfolio, ranked #25.

Torrey Growth & Income Advisors first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Torrey Growth & Income Advisors held 4,710 shares of Vertex Pharmaceuticals worth $2.34M as of Q2 2026.
  • Torrey Growth & Income Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.79% of Torrey Growth & Income Advisors's portfolio in Q2 2026, its #25 holding.
  • Torrey Growth & Income Advisors first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Torrey Growth & Income Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.